Tonix Pharmaceuticals Holding Corp. (NasdaqGM:TNXP) in our automated value investing analysis, with the cash flow history and price comparison below.
Advertisement helps keep Trendshare free for most readers.
Estimate how long you need to hold Tonix Pharmaceuticals Holding Corp. to reach your target.
Hmm, we can't give any reliable projection for Tonix Pharmaceuticals Holding Corp.'s growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.
None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!
| Advantages | Disadvantages | Neutral |
|---|---|---|
| None. |
|
|
| TNXP Price (Tonix Pharmaceuticals Holding Corp. stock price per share) |
$2.55 | |
| PE Ratio versus Sector | 100% lower than other Healthcare stocks | |
| PE Ratio versus Industry | 100% lower than other Drug Manufacturers - General stocks | |
| Free Cash Flow Jitter | 40% |
In the six months to 2026-11-20, 3 insiders bought in 4 trades, about $160 thousand, and no insider sold shares.
The six months before that had 1 buy and 0 sales.
Open-market buys and sells reported by Tonix Pharmaceuticals Holding Corp.'s officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-08-27 | LEDERMAN SETH (Chief Executive Officer) | Buy | 2,000 | $13.79 |
| 2026-06-12 | Taylor Carolyn E. | Buy | 1,415 | $10.55 |
| 2026-06-09 | LEDERMAN SETH (Chief Executive Officer) | Buy | 5,000 | $11.79 |
| 2026-06-08 | Stillwell Richard Newcomb | Buy | 5,000 | $11.65 |
| 2026-03-31 | LEDERMAN SETH (Chief Executive Officer) | Buy | 5,000 | $12.62 |
| 2021-05-25 | Goodman Daniel Wintner | Buy | 5,000 | $1.12 |
| 2021-03-24 | LEDERMAN SETH (Chief Executive Officer) | Buy | 16,733 | $1.32 |
| 2020-08-31 | Treco James | Buy | 5,500 | $0.89 |
| 2020-08-20 | Bell Margaret Smith | Buy | 5,391 | $0.93 |
| 2020-08-17 | SULLIVAN GREGORY M (Chief Medical Officer) | Buy | 20,000 | $1.03 |
This stock has short interest! This means that people have shorted it.
Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.
As of the latest analysis, there are 3,318,461 shares shorted. With 18,268,151 shares available for purchase and an average trading volume over the past 10 trading days of 1,494,860, it would take at least 2.2 days for all of the short holders to cover their shorts.
Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth
How to read this: free cash flow in plain terms, free cash flow jitter.
How to read this: what free cash flow is, why earnings matter.
Net income was negative in all 16 fiscal years from 2010 to 2025, so no ratio of operating cash flow to net income is shown. Operating cash flow totaled -$676 million over those years, against net income of -$840 million.
In 2025, net income was -$124 million and operating cash flow was -$99.8 million, so no ratio is shown for that year.
| Fiscal year | Net income (USD millions) | Operating cash flow (USD millions) | Capital expenditures (USD millions) | Operating cash flow / net income |
|---|---|---|---|---|
| 2010 | -2 | -1.2 | 0 | n/a |
| 2011 | -3.5 | -2.6 | 0 | n/a |
| 2012 | -9.4 | -5.7 | 0 | n/a |
| 2013 | -10.9 | -8.5 | 0 | n/a |
| 2014 | -27.6 | -22.8 | 0.3 | n/a |
| 2015 | -48.1 | -42.5 | 0.1 | n/a |
| 2016 | -38.8 | -37.3 | 0.1 | n/a |
| 2017 | -21.1 | -19.1 | 0 | n/a |
| 2018 | -26.1 | -24 | 0 | n/a |
| 2019 | -28.6 | -26.7 | 0 | n/a |
| 2020 | -50.5 | -48.6 | 8.6 | n/a |
| 2021 | -92.3 | -75.6 | 35.3 | n/a |
| 2022 | -110 | -98.1 | 48.1 | n/a |
| 2023 | -117 | -102 | 7.9 | n/a |
| 2024 | -130 | -60.9 | 0.1 | n/a |
| 2025 | -124 | -99.8 | 3.4 | n/a |
How to read this: earnings and margins.
Revenue was $7.8 million in 2023 and $13.1 million in 2025, a compound annual growth rate of 29.9% over 2 years.
Revenue rose 29.8% from 2024 to 2025.
Our estimated free cash flow was -$119 million in 2025, a negative margin of 906.5% of revenue, meaning the estimate was below zero. In 2023 the estimated margin was negative 1570.4%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.
| Fiscal year | Revenue (USD millions) | Estimated free cash flow (USD millions) | Estimated free cash flow / revenue |
|---|---|---|---|
| 2023 | 7.8 | -122 | -1570.4% |
| 2024 | 10.1 | -80.9 | -801.8% |
| 2025 | 13.1 | -119 | -906.5% |
How to read this: how debt and assets are compared, the current ratio.
In 2025, cash and equivalents were $208 million against total liabilities of $32 million, or 648.4% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.
Total liabilities were 11.6% of total assets in 2025, compared with 195.1% in 2010, a decrease of 183.6 percentage points.
Stockholders equity was $245 million in 2025, up from negative equity of -$0.2 million in 2010.
Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was -307.0% in 2025. Invested capital here is total assets less cash and current liabilities.
| Fiscal year | Total assets (USD millions) | Cash and equivalents (USD millions) | Total liabilities (USD millions) | Stockholders equity (USD millions) |
|---|---|---|---|---|
| 2010 | 0.2 | n/a | 0.4 | -0.2 |
| 2011 | 0.4 | n/a | 2.9 | -2.5 |
| 2012 | 2.1 | 1.8 | 1.2 | 1 |
| 2013 | 8.7 | 8.2 | 2.2 | 6.5 |
| 2014 | 39.5 | 38.2 | 3.5 | 36.1 |
| 2015 | 47 | 19.2 | 6.8 | 40.3 |
| 2016 | 27.5 | 18.9 | 2.1 | 25.4 |
| 2017 | 26.8 | 25.5 | 2.1 | 24.6 |
| 2018 | 26.3 | 25 | 2.7 | 23.7 |
| 2019 | 14.6 | 11.2 | 5.1 | 9.4 |
| 2020 | 98.2 | 77.1 | 10.5 | 87.6 |
| 2021 | 241 | 179 | 22.2 | 219 |
| 2022 | 226 | 120 | 18.5 | 207 |
| 2023 | 154 | 24.9 | 48.9 | 106 |
| 2024 | 163 | 98.8 | 23.3 | 140 |
| 2025 | 277 | 208 | 32 | 245 |
We do not estimate a fair value for Tonix Pharmaceuticals Holding Corp. while its free cash flow growth is not positive, so there is no value comparison here.
None of the 16 fiscal years we have for Tonix Pharmaceuticals Holding Corp. under its current SEC filer shows positive free cash flow.
Year-to-year variability in free cash flow is volatile, measured at 40%.
Before you act on any of this, read what a margin of safety means and check the company's own filings.
We do not have a dividend yield for Tonix Pharmaceuticals Holding Corp..
How to read this: the price to earnings ratio.
Its trailing P/E ratio is 100% below the average for stocks in the Healthcare sector.
Its trailing P/E ratio is 100% below the average for stocks in the Drug Manufacturers - General industry.
A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.
These are companies in the Drug Manufacturers - General industry, the ones closest in market capitalization to Tonix Pharmaceuticals Holding Corp., limited to companies whose pages we publish. The figures come from our latest data for each company.
| Company | Market cap (USD millions) | P/E | Dividend yield | Cash yield | Price versus our estimate |
|---|---|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 49.6 | - | - | - | - |
| LifeVantage Corporation (LFVN) | 62 | 23.3 | 4.0% | - | 85% above |
| SIGA Technologies (SIGA) | 190 | 265.0 | - | 7.1% | 86% below |
| Collegium Pharmaceutical (COLL) | 783 | 23.1 | - | - | 160% above |
| Amphastar Pharmaceuticals (AMPH) | 1,199 | 12.9 | - | 0.8% | 97% above |
| Innoviva (INVA) | 1,309 | 7.8 | - | - | 12% above |
| Phibro Animal Health Corporation (PAHC) | 1,384 | 13.6 | 1.3% | - | 87% above |
Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.
Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.
Every fiscal year on this page is reported by one SEC filer, CIK 1430306.
Each figure on this page comes from that filer.
How to read this: understanding investment risk.
Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.
Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.
The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.
This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.
Read the filings yourself: TNXP annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.
Advertisement supports free stock analysis content.
Does Tonix Pharmaceuticals Holding Corp. have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
This example shows how we apply the Trendshare checklist to TNXP: earnings power, cash generation, valuation, and margin of safety.
We check: business quality, free cash flow, P/E, and margin of safety.
Most Popular Articles
What is Dollar Cost Averaging?
Benjamin Graham, Value Investor
How Do Tariffs Affect the Stock Market?
Precious Metals for Value Investors